Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

18 enrolled 14 charts

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT04880863 2025-03-03

NT-NAP-102-1

38 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03890289 2024-11-21

GAUDEALIS

5 enrolled 13 charts

Lymphoma, Follicular

NCT03311126 2024-10-24

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

21 enrolled 17 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04189588 2023-10-06

versus

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT03145480 2023-06-01

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Other hematologic neoplasm

3 enrolled 5 charts

Leukemia

NCT02225275 2022-09-28

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

9 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02968563 2022-01-21

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

35 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02736617 2022-01-05

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

10 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT02983617 2021-12-21

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

36 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02320487 2020-02-11

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

102 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02071225 2020-02-07

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

72 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02420210 2018-06-06

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

2 enrolled 7 charts

Lymphoma, Large B-Cell, Diffuse

NCT01414855 2018-04-25

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

100 enrolled 17 charts

Lymphoma, B-Cell

NCT01889797 2017-05-05

PrE0401

32 enrolled 14 charts

Indolent Non-Hodgkin's Lymphoma

NCT01414205 2017-04-17

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

80 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01868893 2017-04-17

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

20 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00576758 2014-08-19

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

175 enrolled 31 charts